… dose adjustment was needed because of change in bodyweight. Dose reduction of erlotinib
was allowed for up to two doses … After two steps of dose reduction, erlotinib was discontinued…

… An oral dose of 150 mg once daily is given continuously as second-line therapy in patients
with NSCLC. For patients with pancreatic cancer, the dose of erlotinib is 100 mg daily in …

… an agent, such as erlotinib, with a … first- and second-line FOLFOX therapy for mCRC (28,
29). The present study was initiated to determine the maximum tolerated dose (MTD) of erlotinib …

… Dose reductions and management of expected toxicities were specified in the … dosing
interruption up to 14 days or if patients were unable to tolerate erlotinib at a 50 mg/day dose. …

… dose of radiation, and the sequencing of erlotinib, radiation, and cytotoxic chemotherapy. The
reported patterns and rates … concurrent WBRT and erlotinib to erlotinib alone with WBRT at …

… medication costs it was assumed that, as per the SATURN protocol, patients received a single
daily dose of 150 mg of erlotinib orally (dispensed in packs of 30 tablets). Drug costs were …

… erlotinib was not dose dependent and there was no drug accumulation with the continuous
daily dosing… For many years the standard of care for first line treatment of NSCLC has been …

… doses, 4–6 cycles) (BC arm) or bevacizumab plus erlotinib (po 150 mg/day; BE arm) until
disease progression or unacceptable toxicity. The primary endpoint was progression-free …

… The pharmacokinetics of erlotinib from a phase 1 dose-escalation study was published. The
apparent clearance (CL/F) and volume of distribution were 6.3 L/h and 136.4 L, respectively. …

… erlotinib first line in combination with docetaxel defined the MTD as 200 mg/d. Furthermore,
a study is ongoing to investigate if the dose of erlotinib … dosing flexibility in the clinic, erlotinib …